Treatment of psoriasis. Part 1. Topical therapy and phototherapy

Journal of the American Academy of Dermatology

Volumn 45, Issue 4, 2001, Pages 487-502

  Lebwohl, Mark ^a   Ali, Suad ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIPSORIASIS AGENT; ASCOMYCIN; AZATHIOPRINE; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL PROPIONATE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DIFLORASONE DIACETATE; DITHRANOL; FLUOROURACIL; FUMARIC ACID DERIVATIVE; HYDROCORTISONE; HYDROXYUREA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROPYLTHIOURACIL; PSORALEN; RETINOID DERIVATIVE; SALAZOSULFAPYRIDINE; SALICYLIC ACID; TACROLIMUS; TAR; TAZAROTENE; TIOGUANINE; ULOBETASOL PROPIONATE; UNINDEXED DRUG;

CORTICOSTEROID THERAPY; CREAM; HUMAN; LASER; LIGHT; LOTION; OINTMENT; PHOTOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PUVA; RADIATION CARCINOGENESIS; REVIEW; RISK BENEFIT ANALYSIS; SKIN CANCER; ULTRAVIOLET B RADIATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTHRALIN; ANTI-INFLAMMATORY AGENTS; HUMANS; PHOTOTHERAPY; PSORIASIS; RETINOIDS; RISK FACTORS; VITAMIN D;

EID: 0034805313     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.117046     Document Type: Article

References (99)

1. Treatment of psoriasis
2. Correlation of the vasoconstriction assay and clinical activity in psoriasis
3. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease
4. Fatal iatrogenic Cushing’s syndrome
5. Tachyphylaxis to the action of topically applied corticosteroids
6. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis
7. Intermittent corticosteroid maintenance treatment of psoriasis: A double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen
8. The safety and efficacy of limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas
9. Limited application of mometasone furoate on the face and intertriginous areas: Analysis of safety and efficacy
10. Topical glucocorticoids with improved benefit/risk ratio: Do they exist?
11. Topical glucocorticoids with improved risk-benefit ratio: Rationale of a new concept
12. Betamethasone valerate foam 0.12%: A novel vehicle with enhanced delivery and efficacy
13. Treatment of nummular psoriasis with a clobetasol propionate stick
14. Short-contact treatment at home with Micanol
15. Short-duration ("minutes") therapy with dithranol for psoriasis: A new out-patient regimen
16. The effects of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis
17. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis
18. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis
19. A multicenter trial of calcipotriene ointment and halobetasol ointment to either agent alone for the treatment of psoriasis
20. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: Effects on the duration of improvement
21. Compatibility of calcipotriene with other topical medications
22. Topical calcipotriene in combination with UVB phototherapy for psoriasis
23. Topical calcipotriol combined with phototherapy for psoriasis: The results of two randomized trials and a review of the literature
24. Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris
25. No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis
26. Calcipotriol improves the response of psoriasis to PUVA
27. Interactions between calcipotriene and ultraviolet light
28. A simple method to predict whether topical agents will interfere with phototherapy
29. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis: A randomized, double-blind, parallel group multicenter study
30. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis
31. Topical calcipotriol in the treatment of intertriginous psoriasis
32. Diluting Dovonex
33. Hypercalcaemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol
34. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism: A randomized, double-blind, placebo-controlled study
35. Long-term efficacy and tolerability of topical calcipotriol in psoriasis: Results of an open study
36. Long-term use of topical calcipotriol in chronic plaque psoriasis
37. Topical maxacalcitol for the treatment of psoriasis vulgaris: A placebo-controlled, double-blind, dose-finding study with active comparator
38. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol: A double-blind trial
39. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: Vehicle-controlled study of safety, efficacy, and duration of therapeutic effect
40. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis
41. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid
42. Double-blind comparison of tazarotene gel q.d. Plus mometasone furoate cream q.d. Versus mometasone furoate cream b.i.d
43. A pilot study to determine the effect of tazarotene 0.1% gel on steroid-induced epidermal atrophy
44. In vitro compatibility of tazarotene with other topical treatments of psoriasis
45. Tazarotene in combination with phototherapy
46. Interactions between tazarotene and ultraviolet light
47. Topical corticosteroid compounding: Effects on physiochemical stability and skin penetration rate
48. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: A multicenter study
49. Treatment of psoriasis of the scalp with betamethasone 17, 21-dipropionate plus salicylic acid lotion (’Diprosalic’)
50. Topical 5-fluorouracil treatment for psoriatic trachyonychia
51. Weekly pulse dosing schedule of fluorouracil: A new topical therapy for psoriasis
52. Weekly psoriasis therapy using intralesional fluorouracil
53. Topical tacrolimus is not effective in chronic plaque psoriasis: A pilot study
54. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study
55. A short-term trial of tacrolimus ointment for atopic dermatitis
56. Clearing of psoriasis by a novel immunosuppressive macrolide
57. Topical methotrexate therapy for psoriasis
58. Cryotherapy for psoriasis
59. The approach to psoriasis
60. Components of the Goeckerman regimen
61. Outpatient phototherapy of psoriasis
62. Enhanced response of psoriasis to UVB therapy after pretreatment with a lubricating base: A single-blind controlled study
63. Effects of topical preparations on the erythemogenicity of UVB: Implications for psoriasis phototherapy
64. The validity and practicality of sun-reactive skin types I through VI
65. Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation? A review of the literature
66. Effect of short-contact anthralin therapy on ultraviolet B irradiation of psoriasis
67. Addition of short-contact anthralin therapy to an ultraviolet B phototherapy regimen: Assessment of efficacy
68. Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis
69. Acitretin plus UVB therapy for psoriasis: Comparisons with placebo plus UVB and acitretin alone
70. Duration of remission of psoriasis therapies
71. Oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial
72. Essentials for PUVA therapy: Guidelines for photochemotherapy
73. British Photodermatology Group guidelines for PUVA
74. Standard oral versus bath-psoralens plus ultraviolet A
75. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment
76. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study
77. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study
78. Proceedings of the psoriasis combination and rotation therapy conference. Deer Valley, Utah, Oct 7-9, 1994
79. Evaluation of PUVA, topical corticosteroids and the combination of both in the treatment of psoriasis
80. Controlled study of PUVA and adjunctive topical therapy in the management of psoriasis
81. Acitretin in combination with UVB or PUVA
82. Photochemotherapy for severe psoriasis without or in combination with acitretin: A randomized, double-blind comparison study
83. Retinoids in cancer prevention and therapy
84. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: Response to long-term acitretin maintenance
85. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo-controlled study
86. Combined methotrexate-PUVA therapy in the treatment of psoriasis
87. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study
88. Combination of psoralens and ultraviolet A and ultraviolet B in the treatment of psoriasis vulgaris: A bilateral comparison study
89. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B
90. Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: A paired comparison study
91. The use of narrowband UV-B (tube lamp) in the management of skin disease
92. Assessment of DNA damage induced by broadband and narrowband UVB in cultured lymphoblasts and keratinocytes using the comet assay
93. Dead Sea sun vs. Dead Sea water in the treatment of psoriasis
94. The effect of grenz rays on psoriasis lesions of the scalp: A double blind bilateral trial
95. Carcinomas following Grenz ray treatment of benign dermatoses
96. Skin cancer in the PUVA-48 cooperative study
97. CO2 laser resurfacing of psoriatic plaques: A pilot study
98. 308 nm UVB excimer laser for psoriasis
99. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy